Vice President, Clinical Development

Minal Mehta, MBBS, serves as Vice President, Clinical Development for Avenzo Therapeutics. She has over 20 years of experience in oncology clinical development, most recently as Executive Medical Director at Turning Point Therapeutics which was subsequently acquired by Bristol Myers Squibb (BMS) in August 2022. At Turning Point Therapeutics/BMS, she led the Clinical Development team to develop and secure NDA approval of AUGTYRO™ (repotrectinib).

Dr. Mehta has extensive industry experience in advancing innovative and global oncology programs with a focus on development of targeted therapies for solid tumors. Prior to Turning Point Therapeutics, she held clinical development roles of increasing responsibility at Takeda Oncology (brigatinib, mobocertinib), Idera Pharma (tilsotolimod), AstraZeneca (durvalumab) and Glaxo Smith Kline (ofatumumab) leading clinical assets in early and late stage of development. As a recognized leader in the pharmaceutical industry, her achievements include submission and approvals of several NDAs in BLAs and authoring publications in peer reviewed journals.

Dr. Mehta completed her medical graduation from the University of Mumbai in India.